Discernable differences in the genetic and molecular profile of cerebellar glioblastoma

• Type of Material: Article
• Authors: Muhibullah S Tora, Emory University; David Adamson, Emory University
• Language: English
• Date: 2019-12-01
• Publisher: AME PUBL CO
• Publication Version: Final Published Version
• Copyright Statement: 2019 Translational Cancer Research. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.21037/tcr.2019.08.24
• Title of Journal or Parent Work: TRANSLATIONAL CANCER RESEARCH
• Volume: 8
• Issue: Suppl 6
• Start Page: S553
• End Page: S558
• Grant/Funding Information: None.
• Keywords: Life Sciences & Biomedicine; Oncology; MULTIFORME; Science & Technology; HETEROGENEITY; PROGNOSTIC-FACTORS
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Glioblastoma (GBM) represents the most common primary malignancy of the central nervous system in adults. While the vast majority of GBMs are supratentorial lesions (S-GBM), 0.9% to 3.4% of GBMs occur in the cerebellum (C-GBM) (1-3). Considering this rarity, relatively few studies have examined C-GBMs specifically and the majority of these studies have been understandably limited by small patient populations. Despite sharing many histopathologic characteristics, the question of what degree of clinical and biological similarity there is between C-GBM and S-GBM has been raised (4). In addition, much of the molecular understanding of GBM is restricted to the supratentorial setting. Pursuant to this, studies have highlighted the need for genetic and molecular characterization of C-GBMs (3-8). In the present commentary, we will provide a brief literature review of the clinical demographics and outcomes of C-GBM. In addition, we will highlight and discuss the findings in Cho 2019 and other studies regarding the distinct genetic and molecular profile of C-GBM (8).